Telix Pharmaceuticals Ltd., of Melbourne, Australia, and San Francisco-based Cellsight Technologies Inc. established a collaboration and licensing agreement for Telix to use Cellsight's Visact Immunopet imaging technology in the development of its portfolio of molecularly targeted radiation therapies.

Critical Outcome Technologies Inc., of London, said it closed the first tranche of a nonbrokered private placement with accredited investors primarily from its existing investor base.

The Centers for Medicare & Medicaid Services' Innovation Center issued an informal request for information as it seeks a new direction.

HONG KONG – Research in T-cell therapy has been gaining momentum, with biotech giants like Gilead Sciences Inc. keenly investing in the area. Meanwhile, Lion TCR Pte. Ltd., a smaller company based in Singapore, is also seeing progress with its T-cell therapy treatment for hepatocellular carcinoma (HCC).

Edesa Biotech Inc., a Canadian startup developing dermatology and anorectal therapies, has raised a $7 million series A financing to fund a phase IIb trial of EB-01, a topical secretory phospholipase A2 (sPLA-2) inhibitor therapy it is developing for the treatment of allergic contact dermatitis.

With its first biosimilar stumbling in the murky backstreets of the U.S. biopharma market, Pfizer Inc. is asking a federal court to make Johnson & Johnson (J&J) play by the rules.

Solid efficacy and a distinguishing safety profile – so far, anyway – should give Alnylam Pharmaceuticals Inc. and Sanofi SA an edge over competitor Ionis Pharmaceuticals Inc., analysts said, as the partnered pair scored a top-line phase III win testing RNAi therapy patisiran in hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy.

Before making a mad dash to follow Allergan plc's lead in handing off key patents to an Indian tribe to avoid inter partes reviews (IPRs), other drug and med-tech companies may want to watch from the sidelines to see how the U.S. Supreme Court rules in a case that could doom the entire IPR process.

Incysus Ltd., of New York, submitted an IND application to the FDA for a phase I trial testing its expanded and activated allogeneic gamma-delta T cells in patients with blood cancers following haploidentical stem cell transplantation.

Array Biopharma Inc., of Boulder, Colo., closed its public offering of about 24.1 million shares, including 3.1 million shares issued to cover underwriters' full overallotment option.